Erste Group Bank Decreases Earnings Estimates for Sanofi

Key Points

• Erste Group Bank slightly lowered its FY2026 earnings estimate for Sanofi to $4.95 per share from $4.98, just below the broader consensus estimate of $4.98.
• Analyst sentiment on Sanofi remains mixed, with ratings ranging from Strong Buy to Sell; the stock currently carries an average “Hold” rating and a consensus target price of $51.00.
• Sanofi recently raised its annual dividend to $2.4225 per share from $2.04, while the stock was trading at $43.31, near its 52-week low.

Sanofi (NASDAQ:SNY - Free Report) - Investment analysts at Erste Group Bank dropped their FY2026 earnings per share estimates for shares of Sanofi in a research note issued to investors on Tuesday, May 5th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $4.95 per share for the year, down from their previous forecast of $4.98. The consensus estimate for Sanofi's current full-year earnings is $4.98 per share. Erste Group Bank also issued estimates for Sanofi's FY2027 earnings at $5.30 EPS.

Other research analysts also recently issued research reports about the stock. Bank of America downgraded shares of Sanofi from a "buy" rating to a "neutral" rating in a research note on Thursday, February 12th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of Sanofi in a research note on Friday, January 16th. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research note on Thursday, March 19th. Wall Street Zen downgraded shares of Sanofi from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 21st. Finally, Citigroup reissued a "neutral" rating on shares of Sanofi in a research note on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $51.00.

Sanofi Stock Performance

NASDAQ:SNY opened at $43.31 on Monday. The stock has a fifty day simple moving average of $46.17 and a 200-day simple moving average of $47.76. Sanofi has a 52-week low of $42.78 and a 52-week high of $53.36. The company has a market capitalization of $105.63 billion, a PE ratio of 12.10, a price-to-earnings-growth ratio of 1.07 and a beta of 0.35. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17.

Institutional Trading of Sanofi

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SNY. Flagship Harbor Advisors LLC purchased a new stake in Sanofi in the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. grew its holdings in Sanofi by 180.5% in the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company's stock valued at $28,000 after buying an additional 379 shares during the period. Leonteq Securities AG grew its holdings in Sanofi by 95.8% in the 1st quarter. Leonteq Securities AG now owns 607 shares of the company's stock valued at $29,000 after buying an additional 297 shares during the period. Measured Wealth Private Client Group LLC purchased a new stake in Sanofi in the 3rd quarter valued at about $29,000. Finally, Palisade Asset Management LLC purchased a new stake in Sanofi in the 3rd quarter valued at about $30,000. Hedge funds and other institutional investors own 14.03% of the company's stock.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th will be issued a $2.4225 dividend. This is a positive change from Sanofi's previous annual dividend of $2.04. The ex-dividend date is Monday, May 4th. This represents a yield of 559.0%. Sanofi's dividend payout ratio (DPR) is presently 49.44%.

Sanofi Company Profile

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.